Skip to Main Content
Table 3—

Patient and graft survival according to PTD status in kidney transplant recipients

InvestigatorsYear follow-up began (mean)Immunosuppressive regimenTime at survival estimates (years*)Estimated survival
Patient
Graft
PTD present (%)PTD absent (%)PTD present (%)PTD absent (%)
Arner et al. (27,28) 1975 AZA and prednisone NA NA 38 81 
      69§ 85 
von Kiparski et al. (21) 1978 AZA and prednisone or triple 10 51 93 54 85 
Friedman et al. (25) 1980 AZA and prednisone 67 83 55 55 
Boudreaux et al. (8,9) 1984 AZA and prednisone or triple 71 94 NA NA 
Miles et al. (17) 1983 Triple 12 73 79 46 67# 
Vesco et al. (10,11) 1988 AZA and prednisone or triple 86 93 67 93 
Lanerolle et al. (16) 1993 Triple 85 95 NA NA 
InvestigatorsYear follow-up began (mean)Immunosuppressive regimenTime at survival estimates (years*)Estimated survival
Patient
Graft
PTD present (%)PTD absent (%)PTD present (%)PTD absent (%)
Arner et al. (27,28) 1975 AZA and prednisone NA NA 38 81 
      69§ 85 
von Kiparski et al. (21) 1978 AZA and prednisone or triple 10 51 93 54 85 
Friedman et al. (25) 1980 AZA and prednisone 67 83 55 55 
Boudreaux et al. (8,9) 1984 AZA and prednisone or triple 71 94 NA NA 
Miles et al. (17) 1983 Triple 12 73 79 46 67# 
Vesco et al. (10,11) 1988 AZA and prednisone or triple 86 93 67 93 
Lanerolle et al. (16) 1993 Triple 85 95 NA NA 
*

Number of patients at risk not reported in all studies.

For cadaveric grafts.

P < 0.001.

§

For living donors.

P < 0.05.

RR 12.1; 95% CI 2.2–58.8.

#

Predictors of graft loss (adjusted for age, sex, and ethnicity) were PTD (RR 3.72; P = 0.04) and serum creatinine at 1 year (RR 2.01; P < 0.01). AZA, azathioprine; triple, AZA prednisone and cyclosporine.

Close Modal

or Create an Account

Close Modal
Close Modal